The stars weren't aligned By Eric Pierce
Staff Writer

Buried in Carrington Laboratories' 10-Q was that the CARN was buying back its $6.6 million in convertible preferred shares sold in October. The company completed the transaction on May 21, for $7.8 million. CARN said it elected to spend the $1.2 million to save its common stockholders from dilution. The price tag for the repurchase includes CPA fees, attorney's fees registration fees and the like, according to the company.